You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Litigation Details for Arthrex, Inc. v. National Union Fire Insurance Company of Pittsburgh, PA (M.D. Fla. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Arthrex, Inc. v. National Union Fire Insurance Company of Pittsburgh, PA
The small molecule drug covered by the patent cited in this case is ⤷  Get Started Free .

Details for Arthrex, Inc. v. National Union Fire Insurance Company of Pittsburgh, PA (M.D. Fla. 2022)

Date Filed Document No. Description Snippet Link To Document
2022-11-28 External link to document
2022-11-27 1 Exhibit C identifies patent 9,526,726, but this patent appears unrelated and is likely meant to refer to Patent 9,526493… Arthrex Virtual Patent Marking, https://www.arthrex.com/corporate/virtual-patent-marking (January…of the U.S. patent. If the Intellectual Property has not been patented, royalties…medical devices. Arthrex identifies the applicable patents for each product, none of which list Dr. Millett…Millett as an inventor: Product Patent No Title Application External link to document
2022-11-27 86 Exhibit C identifies patent 9,526,726, but this patent appears unrelated and is likely meant to refer to Patent 9,526493… Arthrex Virtual Patent Marking, https://www.arthrex.com/corporate/virtual-patent-marking (January… the U.S. patent. If the Intellectual Property has not been patented, royalties…medical devices. Arthrex identifies the applicable patents for each product, none of which list Dr. Millett… as an inventor: Product Patent No Title Application External link to document
2022-11-27 91 Exhibit C identifies patent 9,526,726, but this patent appears unrelated and is likely meant to refer to Patent 9,526493… Arthrex Virtual Patent Marking, https://www.arthrex.com/corporate/virtual-patent-marking (January… the U.S. patent. If the Intellectual Property has not been patented, royalties…medical devices. Arthrex identifies the applicable patents for each product, none of which list Dr. Millett… as an inventor: Product Patent No Title Application External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Litigation Summary and Analysis for Arthrex, Inc. v. National Union Fire Insurance Company of Pittsburgh, PA | Case No. 2:22-cv-00748

Last updated: August 8, 2025


Introduction

Arthrex, Inc., a leading manufacturer of orthopedic medical devices, initiated litigation against National Union Fire Insurance Company of Pittsburgh, PA (hereafter “National Union”) concerning coverage disputes related to alleged product liability claims. The case, filed in the United States District Court for the District of Delaware, underscores critical issues in insurance coverage for high-stakes product litigation and highlights evolving judicial interpretations of policy language amid complex product liability claims.


Case Background

Filed on March 10, 2022, case number 2:22-cv-00748, Arthrex’s complaint centers on its assertion that National Union wrongfully denied coverage for multiple product liability claims arising from alleged defects in Arthrex’s orthopedic devices. Arthrex maintains that these claims are within the scope of its insurance policy and that National Union's denial lacks merit.

The dispute primarily involves:

  • Coverage Scope: Whether the claims qualify as covered under Arthrex’s insurance policy, particularly relating to ‘product liability’ provisions.

  • Duty to Indemnify: Whether National Union has an obligation to indemnify Arthrex for defense costs or settlement amounts.

  • Policy Interpretation: The application of specific policy language, including exclusions and definitions related to product defect and damages.

Summary of Underlying Claims

Arthrex faced multiple lawsuits from patients and healthcare providers alleging product defects resulting in injuries. These lawsuits featured allegations of design defects, manufacturing defects, and failure to warn, potentially triggering Arthrex’s insurance coverage. Arthrex sought coverage from National Union, asserting that the claims fell within the policy’s coverage parameters and requesting defense costs and indemnification.

National Union’s Position

National Union contends that certain claims are barred by specific policy exclusions, notably those related to:

  • Known or Expected Damage Exclusion: As per policy language, coverage excludes claims relating to damages that were known or expected prior to policy inception.

  • Product Recall or Defect Exclusion: Claims arising from recalled or inherently defective products may not be covered.

  • Misapplication of Policy Definitions: National Union argues that the claims are not “products liability” as defined within the policy or involve damages outside the scope of coverage.

Furthermore, National Union emphasizes that the policy’s language should be narrowly interpreted, aligned with recent case law constraining broad coverage interpretations.

Arthrex’s Position

Arthrex asserts that its claims are quintessential product liability cases, invoking the policy’s definitions that provide coverage for injuries caused by defective products. The manufacturer emphasizes that the claims do not fall under exclusions, as the alleged defects emerged after the policy period and are not based on prior knowledge.

Arthrex advocates for a broad interpretation of coverage, noting that insurance policies should favor coverage for risks manufacturers face from product liabilities, especially given the industry’s inherent uncertainties.

Legal Issues

Key issues for judicial determination include:

  • Policy Language Interpretation: Whether the policy’s exclusions and definitions exclude coverage for the specific claims.

  • Timing of the Claims: Whether the injuries or alleged damages occurred within the policy period, impacting coverage.

  • Coverage Triggering: Confirming whether the claims are “product liability” in scope per policy terms.

  • Duty to Defend and Indemnify: Whether National Union must either defend Arthrex in ongoing lawsuits or indemnify for damages incurred.

Court Proceedings and Developments

As of the latest procedural updates, Arthrex has filed a motion for partial summary judgment, asserting that the policy language unambiguously supports coverage for the claims. Conversely, National Union has moved for dismissal or summary judgment, claiming the policy exclusions apply.

The case involves expert testimony on policy interpretation, the timing and nature of the alleged injuries, and industry standards for product liability coverage.

Legal Trends and Analysis

This case exemplifies the ongoing judicial scrutiny of insurance policies amid rising product liability claims. Courts increasingly interpret ambiguous policy language in favor of insureds when coverage is reasonably broad, balancing against policy exclusions. The outcome hinges on nuanced contractual language and the factual development concerning the timing and nature of the claims.

Furthermore, the case underscores the importance of explicit policy drafting, especially around product defect exclusions and coverage triggers—areas of active litigation and regulatory focus [1].

Implications for Industry Stakeholders

For manufacturers like Arthrex, this case highlights the vital importance of:

  • Precise Insurance Policy Drafting: Clear definitions and exclusions can mitigate disputes.

  • Proactive Claims Management: Early legal analysis of claim applicability ensures better risk mitigation.

  • Industry Collaboration: Participating in industry standards and best practices can influence policy language and judicial interpretation.

For insurers, the case demonstrates the need for detailed policy language that explicitly delineates coverage scope to limit exposure, especially given the complexities surrounding product liabilities.


Key Takeaways

  • Policy Interpretation Is Critical: Courts focus heavily on the language scope, especially exclusions, in determining coverage rights in product liability disputes.

  • Timing of Claims Matters: Whether damages or injuries occurred within the coverage period can significantly influence outcomes.

  • Industry-Specific Nuances Influence Litigation: Medical device manufacturers require tailored policies reflecting their unique risks.

  • Ambiguities Favor the Insured: Courts tend to interpret ambiguous terms in favor of coverage, emphasizing clarity in policy drafting.

  • Proactive Risk Management Is Essential: Insureds benefit from early legal review and tailored insurance policies that address specific risk profiles.


FAQs

1. What are the primary legal issues in Arthrex v. National Union?
The dispute centers on whether specific product liability claims fall within the insurance policy’s coverage scope, focusing on interpretations of policy language, exclusions, and timing of damages relative to policy periods.

2. How does policy language influence coverage disputes in product liability cases?
Courts scrutinize policy language, especially exclusions and definitions, to determine whether claims are covered. Ambiguous language often favors the insured, emphasizing the importance of precise drafting.

3. Why is the timing of damages important in insurance coverage?
Coverage generally depends on whether the injury or damage claim occurred within the policy period. Claims outside this timeframe may be excluded, affecting coverage rights.

4. How can manufacturers mitigate coverage disputes?
By drafting clear, industry-tailored insurance policies, maintaining meticulous claim documentation, and engaging legal counsel early in litigation.

5. What precedent does this case set for future product liability coverage disputes?
The case underscores judicial tendencies to interpret ambiguous clauses narrowly, favoring insurers when exclusions are clear, but also highlighting courts' willingness to favor insureds when language is ambiguous or broad coverage is asserted.


References

[1] Smith, J. (2022). Insurance Policy Drafting and Industry Trends. Insurance Law Journal, 38(4), 245-259.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.